FTC orders divestiture based on harm to suppliers

The Federal Trade Commission has cleared global healthcare company Grifols to buy Biotest on the condition that it sells certain assets, after raising concerns about harm to the market for the supply of blood as well as the sale of hepatitis B immune globulin.

Get unlimited access to all Global Competition Review content